Akebia Therapeutics, Inc. (AKBA): Long-Term Debt
$48.25M
As of 2025-12-31
$49.56M
As of 2026-06-30
-10.0%
3-year compound annual growth
-12.9%
5-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $48.25M | +24.7% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $38.69M | +11.6% | 2025-03-13, Balance as of period end |
| 2023-12-31 | $34.68M | -47.5% | 2024-03-14, Balance as of period end |
| 2022-12-31 | $66.08M | -32.3% | 2023-08-28, Balance as of period end |
| 2021-12-31 | $97.54M | +1.2% | 2022-03-01, Balance as of period end |
| 2020-12-31 | $96.38M | +27.1% | 2021-02-25, Balance as of period end |
| 2019-12-31 | $75.81M | n/a | 2020-03-12, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $48.25M | +24.7% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $22.68M | -66.7% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $99.00M | +106.3% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $600.0K | -25.0% |
| Harrow, Inc. (HROW) | 2025-12-31 | $250.00M | -4.8% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $220.34M | -5.1% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $146.10M | +20.2% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $291.77M | -1.4% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $209.09M | +3.8% |
Compare AKBA, PBYI, RCUS, ARVN side by side · Screen every company in Pharmaceutical Preparations ↗